The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multiomic analysis for minimal residual disease detection: Addressing challenges in stage II-III colon cancer from COSMOS-CRC-01.
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Yuichiro Tsukada
No Relationships to Disclose
 
Nobuhisa Matsuhashi
No Relationships to Disclose
 
Tatsuro Murano
No Relationships to Disclose
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Masahiro Goto
Honoraria - DAIICHI SANKYO COMPANY,LIMITED; MSD K.K.; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma; Nippon Kayaku; Taiho Pharmaceutical
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Akiyoshi Kanazawa
No Relationships to Disclose
 
Takashi Ohta
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; EA Pharma; Eisai; Merck KGaA; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Research Funding - Takeda
 
Akira Ouchi
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroshi Uchigata
No Relationships to Disclose
 
Chiemi Notake
No Relationships to Disclose
 
Mingyang Cai
Employment - Guardant Health; Roche Sequencing Solutions
Stock and Other Ownership Interests - Guardant Health
 
Shile Zhang
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Thereasa A. Rich
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Kimberly Banks
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Patents, Royalties, Other Intellectual Property - Guardant Health
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)